Search Within

Robert Motzer

Formats
  1. Journal Article (610)
  2. Meeting Abstract (580)
  3. Book Section (20)
  4. Review (13)
  5. Correspondence (7)
  6. Conference Paper (6)
  7. Guidelines (5)
  8. Research Letter (5)
  9. Editorial (4)
  10. Book Whole (2)
Groups
  1. Department of Medicine (1252)
  2. Genitourinary Oncology Service (1252)
  3. Solid Tumor Oncology Division (1252)
  4. Surgery (292)
  5. Urology (283)
  6. Survivorship Research (254)

More Groups

People
  1. George Bosl (182)
  2. Martin Voss (178)
  3. Darren Feldman (158)
  4. Dean Bajorin (128)
  5. Paul Russo (119)
  6. Joel Sheinfeld (110)

More People

Years
  1. 2025 (35)
  2. 2024 (49)
  3. 2023 (47)
  4. 2022 (64)
  5. 2021 (65)
  6. 2020 (65)

More Years

Publications
  1. Journal of Clinical Oncology (448)
  2. Annals of Oncology (81)
  3. BJU International (40)
  4. Cancer (35)
  5. European Journal of Cancer (34)
  6. Clinical Cancer Research (33)

More Publications

Publishers
  1. American Society of Clinical Oncology (451)
  2. Oxford University Press (112)
  3. Elsevier Science, Inc. (111)
  4. Elsevier Inc. (89)
  5. Wiley Blackwell (87)
  6. American Association for Cancer Research (58)

More Publishers

Results (1252)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Quality-adjusted time without symptoms of disease progression or toxicity (Q-TWiST) of nivolumab plus cabozantinib (N+C) versus sunitinib (SUN) in treatment-naïve, advanced/metastatic renal cell carcinoma (aRCC): A post-hoc analysis of CheckMate 9ER (CM 9ER) data
    Meeting Abstract

    Cella, D.; Motzer, R. J.; May, J.; Wallace, J.; Marteau, F.; Kwon, Y.; Rusibamayila, N.; Botteman, M.; Ejzykowicz, F.; Choueiri, T. K.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC)
    Meeting Abstract

    Plimack, E. R.; Hammers, H. J.; Choueiri, T. K.; Rini, B. I.; Motzer, R. J.; Suttner, L.; Perini, R. F.; Rogerio, J. W.; Albiges, L.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Long-term trend of quality-adjusted time without symptoms or toxicities (Q-TWiST) of nivolumab+ipilimumab (N+I) versus sunitinib (SUN) for the first-line treatment of advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Motzer, R. J.; Choueiri, T. K.; May, J.; Kwon, Y.; Rusibamayila, N.; Botteman, M.; Hamilton, M.; Ejzykowicz, F.; Cella, D.
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Immunity to childhood vaccines following high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for germ cell tumors (GCT) with comparison to Hodgkin lymphoma (HL)
    Meeting Abstract

    Feldman, D. R.; Lewis, A. R.; Knezevic, A.; Ali, D.; Bromberg, M.; Aronson, J.; Funt, S. A.; McHugh, D. J.; Motzer, R. J.; Bajorin, D. F.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial
    Meeting Abstract

    Lee, C. H.; Voss, M. H.; Carlo, M. I.; Chen, Y. B.; Reznik, E.; Knezevic, A.; Lefkowitz, R. A.; Shapnik, N.; Tassone, D.; Dadoun, C.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Nivolumab plus cabozantinib (N+C) vs sunitinib for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial
    Meeting Abstract

    Pook, D.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Basso, U.; Shah, A. Y.; Suarez, C.; Porta, C.; Barrios, C.; more...
    Asia-Pacific Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Efficacy of avelumab + axitinib vs sunitinib by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101
    Meeting Abstract

    Haanen, J.; Larkin, J.; Choueiri, T.; Albiges, L.; Rini, B.; Atkins, M.; Schmidinger, M.; Penkov, K.; Thomaidou, D.; Wang, J.; more...
    Asia-Pacific Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Meeting Abstract

    Porta, C. G.; Burotto, M.; Suarez Rodriguez, C.; Bourlon, M. T.; Hsieh, J.; Shah, A. Y.; Hamzaj, A.; Bedke, J.; Pook, D.; Kessler, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Porta, C. G.; Motzer, R.; Ejzykowicz, F.; Blum, S. I.; Hamilton, M.; May, J. R.; Huo, S.; Kral, P.; Ivanescu, C.; Choueiri, T. K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Phase III CLEAR trial in advanced renal cell carcinoma (aRCC): Outcomes in subgroups and toxicity update
    Meeting Abstract

    Choueiri, T. K.; Eto, M.; Kopyltsov, E.; Rha, S. Y.; Porta, C. G.; Motzer, R.; Grünwald, V.; Hutson, T. E.; Méndez-Vidal, M. J.; Hong, S. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save